Proventa International will be gathering over 100 C-Level Directors from a mix of emerging to large Pharmaceutical, Biotechnology & Academic/Research Institutions to help solve their key strategic challenges in the area of Pharmacovigilance.Register Now
The Pharmacovigilance Roundtable Discussions Strategy Meeting is free to attend for qualified end-users. These include Senior Executives of Pharmacovigilance (from medium to large Pharma, Biopharma and Biotech players) as well as thought leaders from Academia and regulatory authorities.
Thought leaders who will benefit from attending include CXOs, EVPs, SVPs, VPs, Executive Directors, Directors and Global Heads responsible for:
– Pharmacovigilance, Risk Management, Drug Safety, Safety Surveillance, Clinical Safety, Patient Safety, Medical & Regulatory Affairs, Compliance, Post Authorisation Safety, Medical Safety, Epidemiology.
Those who do not qualify for complimentary passes, including vendors, exchanges, consultancies and other service providers, can apply here.
Fabio De Gregorio
Vice President, Head, Drug Safety Europe, EU QPPV
Prior to joining Shionogi in 2016, Fabio De Gregorio held various healthcare positions throughout Europe. Most recently, he worked with UBC (a pharmacovigilance service provider), in Geneva and London, and previously, as a QPPV and medical director with Tubilux Pharma S.p.A. in Rome, Italy. In addition to his 14 year experience in pharmacovigilance, he held positions as an associate ophthalmologist with Pannarale Ophthalmic Centre in Italy, and served as a post-graduate resident at different European ophthalmic centres, including Coimbra University (Portugal), Cantonal Hospital of Freiburg (Switzerland), and Barraquer Institute of Barcelona (Spain). Fabio De Gregorio is a GMC registered physician. He specialized in Ophthalmology and earned a PhD in patho-physiology of ocular microcirculation from the University “La Sapienza” of Rome.
Anders Lindholm, MD, PhD
VP, Therapeutic Area Head, Inflammation & Immunology, Drug Safety
Anders received his MD at the Karolinska Institute in Stockholm, from which he also earned a PhD in Clinical Pharmacology and Transplantation Surgery. He practiced as a transplantation surgeon in Sweden. His scientific production includes more than 80 publications in peer reviewed journals. Subsequent to the academic career, Anders spent six years at Novo Nordisk as a Clinical Leader leading successful filings for a rapid acting insulin analogue. For the last 15 years Anders has been TA Safety Head at J&J, Shire and Celgene providing oversight for a department of physicians and scientists developing safety evaluations, benefit-risk assessments, and RMPs.
The Westin Boston Waterfront
425 Summer St, Boston, MA 02210